A detailed history of Citigroup Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 110,189 shares of LCTX stock, worth $61,705. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110,189
Previous 36,094 205.28%
Holding current value
$61,705
Previous $36,000 177.78%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.8 - $1.12 $59,276 - $82,986
74,095 Added 205.28%
110,189 $100,000
Q2 2024

Aug 12, 2024

BUY
$0.89 - $1.47 $9,114 - $15,054
10,241 Added 39.61%
36,094 $36,000
Q1 2024

May 10, 2024

BUY
$0.86 - $1.48 $1,738 - $2,992
2,022 Added 8.48%
25,853 $38,000
Q4 2023

Feb 09, 2024

SELL
$0.91 - $1.35 $99,390 - $147,447
-109,220 Reduced 82.09%
23,831 $25,000
Q3 2023

Nov 09, 2023

SELL
$1.16 - $1.53 $29,835 - $39,351
-25,720 Reduced 16.2%
133,051 $157,000
Q2 2023

Aug 10, 2023

SELL
$1.26 - $1.53 $383,182 - $465,292
-304,113 Reduced 65.7%
158,771 $223,000
Q1 2023

May 11, 2023

SELL
$1.2 - $1.53 $17,148 - $21,863
-14,290 Reduced 2.99%
462,884 $694,000
Q4 2022

Feb 09, 2023

BUY
$1.02 - $1.5 $348,016 - $511,789
341,193 Added 250.91%
477,174 $558,000
Q3 2022

Nov 10, 2022

BUY
$1.13 - $1.77 $148,086 - $231,958
131,050 Added 2657.68%
135,981 $154,000
Q2 2022

Aug 10, 2022

SELL
$1.12 - $1.61 $4,598 - $6,610
-4,106 Reduced 45.44%
4,931 $8,000
Q1 2022

May 12, 2022

SELL
$1.21 - $2.48 $32,149 - $65,893
-26,570 Reduced 74.62%
9,037 $14,000
Q4 2021

Feb 10, 2022

SELL
$1.84 - $2.68 $188,141 - $274,032
-102,251 Reduced 74.17%
35,607 $87,000
Q3 2021

Nov 10, 2021

BUY
$2.26 - $2.86 $311,559 - $394,273
137,858 New
137,858 $347,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $95.1M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.